| P2093 | author name string | Fang Wang | |
| | Li-wu Fu | |
| | Wei-qiang Chen | |
| | Yong-ju Liang | |
| | Yan-jun Mi | |
| | Xiao-dong Su | |
| | Li-sheng Zheng | |
| | Qing-feng Xiang | |
| P2860 | cites work | ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal | Q21246014 |
| | A multidrug resistance transporter from human MCF-7 breast cancer cells | Q22008574 |
| | Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance | Q24645668 |
| | BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy | Q27650860 |
| | The human ATP-binding cassette (ABC) transporter superfamily | Q28204495 |
| | Multidrug resistance in cancer: role of ATP-dependent transporters | Q28208049 |
| | Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function | Q28475378 |
| | Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors | Q29615445 |
| | Targeting multidrug resistance in cancer | Q29616803 |
| | Tumour stem cells and drug resistance | Q29617742 |
| | Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) | Q33194199 |
| | Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. | Q33194953 |
| | Characterization of a side population of cancer cells from human gastrointestinal system | Q33225639 |
| | Biochemical, cellular, and pharmacological aspects of the multidrug transporter | Q33636699 |
| | Structural, mechanistic and clinical aspects of MRP1. | Q33784449 |
| | Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs | Q34060806 |
| | Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients | Q34114767 |
| | The Role of ABC Transporters in Clinical Practice | Q34268081 |
| | VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein | Q34304819 |
| | A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies | Q35011280 |
| | Activation of the PI3K/Akt pathway and chemotherapeutic resistance | Q35046899 |
| | Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. | Q36536479 |
| | Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. | Q36552808 |
| | Therapeutic options to target angiogenesis in human malignancies | Q36634261 |
| | Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2 | Q37119716 |
| | Photodynamic therapy inhibits P-glycoprotein mediated multidrug resistance via JNK activation in human hepatocellular carcinoma using the photosensitizer pheophorbide a. | Q37318005 |
| | Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis | Q37739938 |
| | BIBF 1120 for the treatment of non-small cell lung cancer | Q37750755 |
| | Pharmacology of drugs that alter multidrug resistance in cancer | Q37969138 |
| | Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells | Q38337454 |
| | ERK activation by thymosin-beta-4 (TB4) overexpression induces paclitaxel-resistance | Q38510908 |
| | Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function | Q39877772 |
| | Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. | Q39881351 |
| | Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol | Q40036920 |
| | Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance | Q40050525 |
| | Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo | Q40345597 |
| | Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. | Q40410062 |
| | Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318. | Q40530013 |
| | Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract | Q40536780 |
| | Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. | Q40561425 |
| | P-glycoprotein--a mediator of multidrug resistance in tumour cells | Q41078108 |
| | Pharmacological considerations in the modulation of multidrug resistance | Q41078223 |
| | HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. | Q44450066 |
| | Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance | Q44687014 |
| | Screening novel, potent multidrug-resistant modulators from imidazole derivatives | Q45011364 |
| | The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). | Q46839213 |
| | Effects of modulators of multidrug resistance on the expression of the MDR1 gene in human KB cells in culture | Q59358946 |
| | Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity | Q79849693 |
| | Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors | Q84966132 |
| P433 | issue | 1 | |
| P921 | main subject | multiple drug resistance | Q643839 |
| P304 | page(s) | 33-44 | |
| P577 | publication date | 2011-01-28 | |
| P1433 | published in | Cellular Oncology | Q2160503 |
| P1476 | title | Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance | |
| P478 | volume | 34 | |